(NewsDirect)
Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong speakswith Proactive soon after announcing the first patient has been dosedin the combination cohort of the IMPRINTER study - a clinical trial toevaluate the safety and efficacy of Imugene’s PD1- Vaxx incombination with atezolizumab (Tecentriq®) in patients with non-smallcell lung cancer. She says Tecentriq® has previously shown clinicallymeaningful benefit in various types of lung cancer, with six currentlyapproved indications in the US.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.